

## The Pancreatic Cancer Research Team



## Faculty Profiles



**Dr. John L. Cameron, The Alfred Blalock Distinguished Service Professor, served a chair of the Department of Surgery from 1984 to 2003. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958 and his medical degree from Hopkins' School of Medicine in 1962. Except for two years at the Walter Reed Army Institute of Research, Dr. Cameron has spent his entire medical career at Johns Hopkins. He has been a leader in alimentary tract surgery and specifically surgery for pancreatic cancers. Dr.**

**Cameron pioneered efforts to lower the mortality and morbidity of pancreaticoduodenectomy—the Whipple Operation. National leadership positions held include being President of the Society for Surgery of the Alimentary Tract, President of the Southern Surgical Association, President of the Society for Clinical Surgery, President of the Society of Surgical Chairmen, President of the Halsted Society, and Past President of the American Surgical Association.**



**Dr. James Eshleman is an Associate professor of Pathology and Oncology. He is the Associate Director of the Molecular Diagnostic Laboratory at Johns Hopkins. His research is focused on the application of cutting edge molecular genetics to the war against pancreatic cancer. He developed a novel gene-based method to screen for early pancreatic cancer (called “LigAmp”), and he currently is using genome wide technologies to screen for novel compounds to treat pancreatic cancer.**



**Dr. Michael Goggins is a 1988 graduate of the University of Dublin, Trinity College. He did his internal medicine residency and a fellowship in gastroenterology at St. James' Hospital in Dublin. Dr. Goggins was a Lecturer in Medicine at Trinity College from 1992 to 1995. He obtained his Membership of the Royal College of Physicians of Ireland in 1991 and his European Diploma in Gastroenterology in 1995. The subject of his medical thesis was the characterization of protein methylation in human brain. Dr. Goggins is an Associate Professor of Pathology, Medicine and Oncology, and is the Director of the Pancreatic Cancer Early Detection Laboratory at Johns Hopkins. His research interests include using molecular approaches for the early detection of pancreatic cancers. Areas of particular interest include DNA methylation, proteomics and the role of inherited BRCA2 mutations in pancreatic cancer as well as characterizing key molecular genetic and epigenetic events that are required for pancreatic cancers to develop.**



**Dr. Manuel Hidalgo is a 1992 graduate of the University of Navarra, Spain. He did his training in Internal Medicine/Medical Oncology at the University Hospital in Madrid followed by a subspecialty fellowship in Anticancer Drug Development at the University of Texas Health Science Center. His work has focused on the development of novel targeted agents including inhibitors of the epidermal growth factor receptor and other signaling pathways. Dr. Hidalgo joined Johns Hopkins in 2001, and is currently Associate Professor of Oncology and Director of Clinical Research of the GI Program. He is interested in drug development for pancreaticobiliary cancers.**



**Dr. Ralph H. Hruban received his undergraduate training from the University of Chicago and his medical degree from Johns Hopkins. Dr. Hruban completed his residency training in Anatomic Pathology at Johns Hopkins, followed by a Fellowship in Surgical Pathology at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Hruban is a Professor of Pathology and of Oncology at Hopkins' School of Medicine practicing surgical pathology with a subspecialty interest in pancreatic pathology. He is the Director of the Division of Gastrointestinal Pathology, Deputy Director of the Department of Pathology and the Director of the National Familial Pancreas Tumor Registry. Dr. Hruban has published over 350 peer-reviewed papers, and has received four teaching awards from Hopkins' School of Medicine. He received the 2001 Young Investigator Award from the United States and Canadian Academy of Pathology, and in 2002 he received the Arthur Purdy Stout Society Prize for his work on pancreatic malignancies.**



**Dr. Christine Iacobuzio-Donahue received her undergraduate degree from Adelphi University and her medical degree and Ph.D. from Boston University School**

**of Medicine. She completed a residency in anatomic pathology and a Fellowship in Gastrointestinal/Liver Pathology at Johns Hopkins Hospital. In addition to her clinical training, Dr. Iacobuzio-Donahue also spent one year as a postdoctoral fellow in Oncology studying the molecular genetics and gene expression profiles of pancreatic cancer. Dr. Iacobuzio-Donahue is currently an Assistant Professor of Pathology and Oncology at Johns Hopkins. In addition to her clinical responsibilities as a gastrointestinal pathologist, Dr. Iacobuzio-Donahue spends the majority of her time focused on research regarding the genetics, molecular and cellular biology of pancreatic cancer metastasis and is Director of the Gastrointestinal Cancers Rapid Medical Donation Program. Dr. Iacobuzio-Donahue has published 30 peer-reviewed papers and has received several training and career development awards while at Johns Hopkins.**



**Dr. Elizabeth M. Jaffee received her undergraduate training from Brandeis University in Waltham, Massachusetts and her medical degree from New York Medical College in Valhalla, New York. She completed her residency training in internal medicine at The University of Pittsburgh in Pittsburgh, Pennsylvania, followed by a Fellowship in Medical Oncology at Johns Hopkins. Dr. Jaffee is a Professor of Oncology, Immunology, Pathology, Pharmacology, and Cell and Molecular Medicine at Johns Hopkins. She currently practices medical oncology with a subspecialty interest in pancreatic cancer. Dr. Jaffee has an active research program devoted to the development of novel vaccine treatments that activate a patient's immune system to fight their own cancers. She is also the Medical Director of the Good Manufacturing Practices Facility at Hopkins that produces new clinical treatments for testing inpatients. Dr. Jaffee has published over 50 peer-reviewed papers and has received two teaching awards. She was recently named the first recipient of the Dana and Albert "Cubby" Broccoli Chair in Oncology.**



**Dr. Scott E. Kern received his undergraduate and medical degrees from the University of Michigan. After graduating, he obtained his residency training in Anatomic and Clinical Pathology from the University of Michigan. He completed a fellowship in gastrointestinal pathology and molecular biology at Johns Hopkins, where he trained with Dr. Bert Vogelstein. His postdoctoral studies at Hopkins concerned p53, the most frequently mutated gene in human cancer, and he discovered the specific DNA-binding function that is inhibited by the mutations in tumors. Dr. Kern is now a Professor of Oncology and Pathology, and focuses his research interests on the genetic changes that cause pancreatic cancers and account for their behavior. He has appointments in the clinical departments of Oncology and Pathology at Johns Hopkins, as well as the basic science programs in Human Genetics and in Pathobiology. Dr. Kern has authored more molecular biology papers on pancreatic cancer than any other scientist and leads the prestigious Specialized Program of Research Excellence (SPORE) program in gastrointestinal malignancies at Hopkins.**

**Dr. Alison Klein in the Departments of Oncology and Pathology heads the National Familial Pancreas Tumor Registry at Johns Hopkins. Over 1,700 families have joined this registry allowing Dr. Klein to study, in great detail, why pancreatic cancer runs in some families. Just as we get our hair color and eye color from our parents, so too do some individuals appear to inherit an increased risk of developing pancreatic cancer. Dr. Klein has developed a program (called PancPRO) which can be used to calculate this increased risk precisely, and she is now actively hunting for the familial pancreatic cancer gene. Her research includes studies of large populations as well as smaller studies of specific families.**



**Dr. Dan Laheru is an Assistant Professor in Medical Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He received his medical degree from Baylor College in 1995 and completed his residency in internal medicine at The University of Utah. He completed his fellowship in medical oncology at Hopkins in 2001 and was mentored by Dr. Elizabeth Jaffee. His most recent awards include the 2000 AACR Bristol-Myers Squibb Oncology Fellowship in Clinical Research and a 2000 ASCO Young Investigator Award. He was awarded a competitive NIH K23 mentored patient-oriented research career development award in 2002 that is fully dedicated to studying potential new therapies for the treatment of pancreaticobiliary cancers.**




**Dr. Steven D. Leach graduated from Princeton University in 1982 with a magna cum laude degree in biology. He was an Alpha Omega Alpha graduate of Emory University School of Medicine in 1986, and subsequently completed his internship and residency in General Surgery at Yale University School of Medicine. Dr. Leach pursued fellowship training in Surgical Oncology at the M.D. Anderson Cancer Center in Houston where he received the Lotzova Memorial Prize for Excellence in Research and the American Cancer Society Fellowship Prize in recognition of Outstanding Clinical Performance. Dr. Leach joined the faculty in the Department of Surgery at Johns Hopkins in 2000 and became Chief of the Division of Surgical Oncology in 2001, and the first Paul K. Neumann Professor in Pancreatic Cancer. Dr. Leach has published extensively on the diagnosis, treatment and staging of pancreatic cancer. He has been particularly interested in the area of early detection and imaging, as well as novel surgical techniques for resection of**

locally advanced lesions. He currently directs an NIH-funded research program investigating epithelial stem cells and precursor lesions in pancreatic cancer. Dr. Leach has identified important links between mechanisms regulating normal pancreatic development and the initiation of human pancreatic cancer. In conjunction with a large group of talented investigators at Hopkins, his research is directed at identifying fundamental mechanisms responsible for pancreatic cancer initiation, in hope of developing effective means for pancreatic cancer prevention, early detection and cure.



**Dr. Anirban Maitra is an Associate Professor in the Division of Gastrointestinal Pathology at Johns Hopkins. He graduated from the All India Institute of Medical Sciences in New Delhi, India in 1996. He received his training in anatomic pathology at the University of Texas Southwestern Medical Center in Dallas, and specialized in gastrointestinal pathology during his fellowship at Johns Hopkins. Dr. Maitra is the Principal Investigator of the first Biliary Cancer Research Laboratory at Johns Hopkins, which is entirely dedicated to studying the molecular pathogenesis of these tumors and identifying novel cellular targets for therapy. Dr. Maitra has completed several “firsts” in biliary cancer research, including the first global gene expression profiling of these cancers using microarrays, the first array CGH analysis of biliary cancers, and establishment of the first panel of biliary cancer xenografts and cell lines in the United States. His most recent research initiative was identification of the embryonic Hedgehog pathway as a therapeutic target in biliary cancers, which was published in the renowned scientific journal *Nature*. Dr. Maitra’s ongoing work involves development of an animal model for biliary cancer, and identification of novel genetic, epigenetic, and proteomic markers in bile and serum for early detection. Dr. Maitra recently received The 2006 Maryland Outstanding Young Scientist Award.**



**Dr. Akhilesh Pandey is in the McKusick-Nathans Institute of Genetic Medicine and Departments of Biological**

**Chemistry and Oncology. Dr. Pandey's research focuses on the use of mass spectrometry to identify biomarkers in pancreatic cancers. This field of research is known as "proteomics." He also uses bioinformatics, large databases and genome annotation approaches to understand better the causes of pancreatic cancer.**